Polarean, Inc.

02/27/2026

300 million people worldwide are living with rare diseases. Many of these conditions affect the lungs and the ability to breathe, impacting both children and adults.

For patients and families, the journey often includes long diagnostic paths, uncertainty, and the need for ongoing monitoring. More sensitive ways to understand lung function earlier in disease progression can play an important role in supporting care over time.

Some people living with rare lung and cardiopulmonary conditions may struggle to perform spirometry consistently. If you’re interested in learning more about a low-effort lung function assessment that can be completed in a single 10–15 second breath-hold, we welcome you to connect with us.

On Rare Disease Day, we stand with patients, families, clinicians, and researchers working to advance understanding, improve monitoring, and move toward better outcomes for rare lung disease.

Learn more: https://www.rarediseaseday.org/

02/19/2026

We’re excited to share that our CEO, Christopher von Jako, PhD, will be presenting at !

LSI USA brings together healthcare leaders, innovators, and investors to explore what’s next in medtech. We look forward to sharing how Polarean’s platform is advancing functional lung imaging and helping deliver new insights into pulmonary health.

If you’ll be attending LSI USA ’26, we’d love to connect.

Want to learn more or get in touch with our team?
👉 https://xenoview.net/customer-support/

02/12/2026

Did you catch Polarean’s platform featured in the January/February issue of Radiology Today Magazine?

In the article, our CEO Christopher von Jako, PhD, shares how Xenon MRI is advancing functional lung imaging by capturing ventilation images in 10 seconds or less ⏱️ and delivering regional functional insight that conventional imaging and spirometry often can’t provide.

“We’re imaging the gas, not the water content or tissue signal in the lung. If there’s any place where the xenon can’t get to, oxygen is not getting there either,” Chris explains.

This noninvasive, radiation-free technology is opening new doors for visualizing lung function and is being explored across clinical and research settings for conditions including asthma, COPD, cystic fibrosis, and unexplained breathlessness, in adults and children as young as 6. 🫁

👉 Read the full article:
https://www.radiologytoday.net/archive/rt_JF26p6.shtml

Radiology Today newsmagazine reaches 40,000 radiology professionals nationwide on a monthly basis, covering areas such as Radiology Management, Bone Densitometry, Mammography, MRI, PACS, CT, Sonography, Nuclear Medicine, Radiation Oncology, Radiation Therapy, contrast agents, and more!

02/10/2026

We’re excited to be exhibiting at the Society of Thoracic Radiology ( ) Annual Meeting this February 21–25 in Puerto Rico!

STR 2026 features a robust agenda spanning thoracic oncology, interstitial lung disease, cardiopulmonary imaging, AI, and emerging MRI techniques, including a dedicated session on and clinical implementation with Alan Ropp, MD, MS from UVA Health.

If you’ll be attending STR, stop by our exhibit and connect with the team:

🔹 Alan Huang, Vice President Sales
🔹 Daniel Booker, Central Sales Director
🔹 J. Fernando Corredor, Western Sales Director

We’d love to discuss how functional lung MRI is being integrated into clinical practice and research.

Want to connect with our team or learn more about Xenon MRI? Reach out here:
👉 https://xenoview.net/customer-support/

02/04/2026

We had a great time connecting with the community at the 11th Annual Xenon MRI Clinical Trials Consortium (XeCTC) Meeting last week, where clinicians, researchers, and industry partners came together to share advances in functional lung imaging and clinical implementation.

As lead sponsor, Polarean was proud to support a dynamic agenda focused on:

✔️ Emerging clinical applications of Xenon MRI across pulmonary and cardiopulmonary disease
✔️ Real-world implementation and workflow considerations
✔️ New research exploring functional imaging biomarkers
✔️ Collaboration to advance adoption and evidence generation

Thank you to for all the presenters and attendees for the engaging discussions and shared commitment to improving lung health through innovation.

We’re excited to continue working with the XeCTC community to help move functional lung MRI forward in both research and clinical practice.

Want to learn more about Xenon MRI? Connect with us here:
👉 https://xenoview.net/customer-support/

02/03/2026

February is American Heart Month ❤️

The heart and lungs function as a closely connected system. Growing research shows that changes in lung function can reflect cardiovascular stress and risk, highlighting the importance of understanding cardiopulmonary health together, not in isolation.

At Polarean, our platform delivers detailed, noninvasive, radiation-free insight into lung function, offering a new way to visualize and better understand diseases that impact both the heart and lungs.

This Heart Month, we’re celebrating innovation that supports a more connected, patient-centered view of cardiopulmonary health.

🌟 Explore the heart–lung connection and ways to protect both: https://www.lung.org/blog/heart-lung-relationship

🌟 Want to learn more about Xenon MRI or connect with our team? Reach out here: https://xenoview.net/customer-support/



American Heart Association

01/29/2026

Pulmonary hypertension ( ) is a serious, life-threatening disease that puts extreme strain on the heart and lungs. The diagnosis and follow-up of patients with PH is challenging due to the absence of clear biomarkers that reflect the complexity of its underlying pathophysiology.

New research from Duke University by Fawaz Alenezi, Anna Costelle, Seth Lee, Bastiaan Driehuys, and Sudarshan Rajagopal is exploring investigational uses of Xenon MRI to study gas exchange and lung microvascular function in PH. This area of active research may deepen understanding of this complex disease and support the development of quantitative imaging biomarkers.

The authors describe how may:

✔️ Reveal regional functional abnormalities not seen with conventional imaging
✔️ Provide insight into different PH subtypes through gas exchange metrics
✔️ Capture early physiologic changes in the disease and treatment response

📖 Read the study: https://pubmed.ncbi.nlm.nih.gov/40600715/

01/20/2026

📣 Polarean Expands Xenon MRI into Cardiopulmonary Drug Development

Polarean has reached an important milestone by expanding the platform into pharma-sponsored cardiopulmonary drug development through a multi-center U.S. study in pulmonary hypertension associated with interstitial lung disease (PH-ILD).

In collaboration with a leading cardiopulmonary pharmaceutical company and VIDA, this work leverages quantitative Xenon MRI biomarkers to directly measure treatment effects at the pulmonary capillary level, an area of lung physiology that has historically been difficult to assess with conventional tools.

🔬 Xenon MRI has the potential to support:

❇️ Early pharmacodynamic readouts in clinical studies
❇️ Differentiation between inhaled and systemic therapies based on mechanism of action
❇️ Improved patient characterization as predominantly left-heart disease (post-capillary) or right-heart disease (pre-capillary)
❇️ Greater endpoint sensitivity in cardiopulmonary clinical trials

By pairing an inhaled therapy with an inhaled imaging signal, Xenon MRI delivers a noninvasive, radiation-free approach to quantify regional functional changes in lung ventilation, gas diffusion across the interstitial membrane, pulmonary capillary blood volume, and microvascular hemodynamics, all within a short breath hold.

This expansion highlights Xenon MRI’s growing role as a powerful imaging biomarker platform for cardiopulmonary drug development, supporting precise evaluation of therapies in diseases with high unmet need.

Read the full announcement:https://polarean.com/wp-content/uploads/2026/01/Polarean-Expands-Xenon-MRI-Platform-into-Cardiopulmonary-Drug-Development_2026-01-20.pdf

Arun Jose, MD, MS, University of Cincinnati, Sudar Rajagopal, MD, PhD, Duke University, Leslie Spikes, University of Kansas Medical Center

01/14/2026

New Insights into Pediatric Lung Diseases Using

In the first of its kind exploratory study, Cincinnati Children's looked at how Xenon MRI can be used in pediatric patients with childhood interstitial and diffuse lung diseases (chILD), specifically Neuroendocrine Cell Hyperplasia of Infancy (NEHI). The results from the research study showed that Xenon MRI can effectively reveal ventilation heterogeneity and interstitial tissue abnormalities in these patients, making it a valuable diagnostic tool, especially for conditions like NEHI, where traditional imaging may fall short.

Read the paper 🔍
https://onlinelibrary.wiley.com/doi/epdf/10.1002/ppul.27410

chILD Foundation - Childrens Interstitial and Diffuse Lung Disease


Children’s Interstitial Lung Disease Foundation

01/12/2026

✨ New Peer-Reviewed Evidence: Xenon MRI Predicts Cystic Fibrosis Exacerbations ✨

A newly published American College of Chest Physicians study shows that ventilation defects can independently predict future pulmonary exacerbations in people with cystic fibrosis ( ), beyond prior clinical history and spirometry results.

The findings highlight how advanced imaging can reveal functional lung changes that conventional tests may miss—particularly in patients with mild or gradual decline.

This work reflects broader priorities across the cystic fibrosis community to advance sensitive, quantitative biomarkers that support personalized care and more efficient clinical trials.

At Polarean, our Xenon MRI platform is designed to bring precise, functional lung imaging into routine clinical practice, helping clinicians visualize physiologic details that matter for early intervention and monitoring.

Read the press release:https://polarean.com/wp-content/uploads/2026/01/Chest-Journal-Study-Demonstrates-Xenon-MRI-Predicts-CF-Exacerbations_2026-01-12.pdf

01/07/2026

✨ 2026: The Year of Xenon MRI ✨

Xenon MRI is transforming how lung function is visualized, moving beyond anatomy to reveal functional insights from a single breath-hold. By making the invisible visible, it enables sensitive detection, clear monitoring, and deep understanding of lung disease.

With growing clinical adoption, 2026 is set to be a defining year for functional lung imaging and patient care.

Learn more: xenoview.net

12/23/2025

As 2025 comes to a close, we want to thank our incredible team and partners for your dedication, creativity, and collaboration. 👏 Together, you are helping advance our mission to revolutionize pulmonary medicine through direct visualization of lung function!

This holiday season, we’re celebrating the people behind the innovation. The faces, energy, and teamwork that power Polarean and make progress possible. From everyday moments to major milestones, it’s the shared commitment that continues to move our mission forward.

Happy Holidays from all of us at Polarean! 💙